C-Terminal Truncated HBx Facilitates Oncogenesis by Modulating Cell Cycle and Glucose Metabolism in FXR-Deficient Hepatocellular Carcinoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24065174 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Xuejun Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shantou University Medical College, Shantou 515041, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Science and Technology Planning Project of Guangdong Province Special Project Fund.
Abstract (Originalsprache)
Farnesoid X receptor (FXR) is a nuclear receptor known to play protective roles in anti-hepatocarcinogenesis and regulation of the basal metabolism of glucose, lipids, and bile acids. FXR expression is low or absent in HBV-associated hepatocarcinogenesis. Full-length HBx and HBx C-terminal truncation are frequently found in clinical HCC samples and play distinct roles in hepatocarcinogenesis by interacting with FXR or FXR signaling. However, the impact of C-terminal truncated HBx on the progression of hepatocarcinogenesis in the absence of FXR is unclear. In this study, we found that one known FXR binding protein, a C-terminal truncated X protein (HBx C40) enhanced obviously and promoted tumor cell proliferation and migration by altering cell cycle distribution and inducing apoptosis in the absence of FXR. HBx C40 enhanced the growth of FXR-deficient tumors in vivo. In addition, RNA-sequencing analysis showed that HBx C40 overexpression could affect energy metabolism. Overexpressed HSPB8 aggravated the metabolic reprogramming induced by down-regulating glucose metabolism-associated hexokinase 2 genes in HBx C40-induced hepatocarcinogenesis. Overall, our study suggests that C-terminal truncated HBx C40 synergizes with FXR deficiency by altering cell cycle distribution as well as disturbing glucose metabolism to promote HCC development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Shantou University Medical College, Shantou 515041, China.
- School of Public Health, Shantou University, Shantou 515063, China.
- Department of Experimental Animal Center, Medical College of Shantou University, Shantou 515041, China.
ORCID-Profile: Zhengzhong Ni, Yongdong Niu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Science and Technology Planning Project of Guangdong Province Special Project Fund
Zitieren
APA
Wu, X., Ni, Z., Song, T., Lv, W., Chen, Y., Huang, D., Xie, Y., Huang, W., & Niu, Y. (2023). C-Terminal Truncated HBx Facilitates Oncogenesis by Modulating Cell Cycle and Glucose Metabolism in FXR-Deficient Hepatocellular Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065174
Vancouver
Wu X, Ni Z, Song T, Lv W, Chen Y, Huang D, et al. C-Terminal Truncated HBx Facilitates Oncogenesis by Modulating Cell Cycle and Glucose Metabolism in FXR-Deficient Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065174
BibTeX
@article{Wu2023,
author = {Wu, Xuejun and Ni, Zhengzhong and Song, Tiantian and Lv, Wenya and Chen, Yan and Huang, Danmei and Xie, Yangmin and Huang, Weiyi and Niu, Yongdong},
title = {C-Terminal Truncated HBx Facilitates Oncogenesis by Modulating Cell Cycle and Glucose Metabolism in FXR-Deficient Hepatocellular Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24065174}
}
EUVIMED